Loading stock data…
$0.45-0.00 (-0.16%)
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States.
Oragenics, Inc. in the Healthcare sector is trading at $0.45 with a market capitalization of $2M. The stock is currently near its 52-week low of $0.44, remaining 29.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$2.26M↑ | -$2.50M↑ | -$3.12M↓ | -$1.71M |
| Net Income | — | -$2.20M↑ | -$2.29M↑ | -$3.07M↓ | -$2.27M |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non...